ATRT-23. SMARCB1-DEPENDENCIES IN ATYPICAL TERATOID/RHABDOID TUMOURS: A STRATEGY FOR PRE-CLINICAL THERAPEUTIC TARGET IDENTIFICATION IN THE ABSENCE OF ACTIONABLE MUTATIONS

ATRTs have low mutation rates and few classically-actionable variants to direct molecularly targeted therapies; loss of SMARCB1 is the sole recurrent mutational event in >90% of ATRTs. We have designed and implemented a genome-scale strategy for target identification and prioritization in tumors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Finetti, Martina Anna, Selby, Matthew p, Pons, Alicia del-Carpio, Batting, Sarah, Wood, James A, Barker, James M, Smith, Amanda, Crosier, Stephen, Bashton, Matthew, Pickles, Jessica C, Fairchild, Amy R, Avery, Aimee, O’Hare, Patricia, Pizer, Barry, Brennan, Bernadette, Lowis, Stephen, Hargrave, Darren, Jacques, Thomas S, Bailey, Simon, Clifford, Steven C, Williamson, Daniel
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2018
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012497/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.021
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge